Agilent Unveils Biopharma CDx Services Lab to Accelerate Precision Medicine
Agilent Technologies
New CLIA-certified lab ensures seamless transition from early assay development and testing to full companion diagnostics commercialization
Drug Development
AACR, ASA, and FDA Outline Considerations for Overall Survival Analyses in Clinical Trials
American Association for Cancer Research
New article outlines best practices, novel statistical methods, and suggestions for improving benefit-risk assessments in clinical trials
New Drug Slows Rare, Debilitating Genetic Disease in Trials
National Institutes of Health
The NIH-supported clinical trial could lead to the first effective treatment for ACDC disease
How Automation Is Transforming Clinical Research Operations
Colin Weller, BSc/BA
Automation, AI, and digital health technologies can help make clinical trials more efficient, inclusive, and impactful
The “Reactome” May Accelerate AI-Based Drug Development
University of Cambridge
Per the first author, "the reactome could change the way we think about organic chemistry."
Genetic Priority Score Finetunes Drug Development
Icahn School of Medicine at Mount Sinai
Innovative approach integrates genetic data to identify drug targets with high potential for clinical trial success
AI’s Impact on Drug Development: Opportunities for Pharmaceutical Leaders
Claire Aldridge, PhD
Explore the transformative impact of artificial intelligence on drug development and its role in the future of pharmaceutical innovation
Novel Drug Improves Rare Kidney Disorder in Phase 3 Trial
University of Minnesota Medical School
Some 42 percent of patients treated with sparsentan showed reduced proteinuria
FDA Approves Interchangeable Biosimilar for Multiple Inflammatory Diseases
U.S. Food and Drug Administration
Wezlana has similar safety and efficacy as its reference product and is a cost-effective alternative for chronic inflammation
Antibody-Drug Conjugate Benefits HER2-Low Breast Cancers
German Institute for Quality and Efficiency in Health Care (IQWiG)
Patients with HER2-low breast cancers were included in the clinical trial proving the efficacy of trastuzumab deruxtecan monotherapy